Immune checkpoint inhibitors, combined with anti-angiogenic agents or locoregional treatments (e.g., transarterial chemoembolization (TACE)), are expected to become standard-of-care for unresectable hepatocellular carcinoma (HCC). We measured the plasma levels of 16 soluble checkpoint proteins using multiplexed fluorescent bead-based immunoassays in patients with HCC who underwent lenvatinib (n = 24) or TACE (n = 22) treatment. In lenvatinib-treated patients, plasma levels of sCD27 (soluble cluster of differentiation 27) decreased (p = 0.040) and levels of sCD40 (p = 0.014) and sTIM-3 (p < 0.001) were increased at Week 1, while levels of sCD27 (p < 0.001) were increased significantly at Weeks 2 through 4. At Week 1 of TACE, in addition to sCD27 (p = 0.028), sCD40 (p < 0.001), and sTIM-3 (soluble T-cell immunoglobulin and mucin domain–3) (p < 0.001), levels of sHVEM (soluble herpesvirus entry mediator) (p = 0.003), sTLR-2 (soluble Toll-like receptor 2) (p = 0.009), sCD80 (p = 0.036), sCTLA-4 (soluble cytotoxic T-lymphocyte antigen 4) (p = 0.005), sGITR (soluble glucocorticoid-induced tumor necrosis factor receptor) (p = 0.030), sGITRL (soluble glucocorticoid-induced TNFR-related ligand) (p = 0.090), and sPD-L1 (soluble programmed death-ligand 1) (p = 0.070) also increased. The fold-changes in soluble checkpoint receptors and their ligands, including sCTLA-4 with sCD80/sCD86 and sPD-1 (soluble programmed cell death domain–1) with sPD-L1 were positively correlated in both the lenvatinib and TACE treatment groups. Our results suggest that there are some limited differences in immunomodulatory effects between anti-angiogenic agents and TACE. Further studies from multicenters may help to identify an effective combination therapy.
<b><i>Introduction:</i></b> Lenvatinib has been approved as a systemic therapy for patients with unresectable hepatocellular carcinoma (HCC). We recently experienced lenvatinib-induced tumor-related hemorrhage in patients with HCC. The full details of tumor-related hemorrhage as a lenvatinib-related adverse event have not been elucidated. <b><i>Methods:</i></b> This was a retrospective single-center study that enrolled consecutive patients treated with lenvatinib for unresectable HCC from April 2018 to February 2020. <b><i>Results:</i></b> Sixty-eight consecutive patients were enrolled in this study. Among them, 5 cases developed intraperitoneal or intratumoral hemorrhages. The patients with hemorrhage had larger tumors (maximum tumor size, 97.5 ± 46.4 and 38.2 ± 28.8 mm, respectively; <i>p</i> = 0.009) than the patients without hemorrhage. The dosing period of lenvatinib (median, 3 and 93 days, respectively; <i>p</i> < 0.001) and the survival time from initial administration of lenvatinib (median, 77 and 495 days, respectively; <i>p</i> < 0.001) of the patients with hemorrhage were shorter than those of the patients without hemorrhage. Especially, in 4 cases with large HCCs (maximum tumor diameter was >90 mm), tumor hemorrhage with vascular lake-like phenomenon was evident, although most tumor blood flow was suppressed. <b><i>Discussion/Conclusion:</i></b> It becomes clear that lenvatinib treatment brings about tumor-related hemorrhages despite rapid suppression of tumor blood flow. We speculate that lenvatinib quickly blocks the feeding circulation, resulting in tumor hemorrhage by necrosis. Clinicians should pay careful attention to the development of life-threatening hemorrhages when treating large HCCs with lenvatinib.
The functions of genes involved in idiopathic portal hypertension (IPH) remain unidentified.
The present study was undertaken to identify the functions of genes expressed in blood
samples from patients with IPH through comprehensive analysis of gene expression using
DNA microarrays. The data were compared with data from healthy individuals to explore the
functions of genes showing increased or decreased expression in patients with IPH. In cluster
analysis, no dominant probe group was shown to differ between patients with IPH and healthy
controls. In functional annotation analysis using the Database for Annotation Visualization
and Integrated Discovery tool, clusters showing dysfunction in patients with IPH involved
gene terms related to the immune system. Analysis using network-based pathways revealed
decreased expression of adenosine deaminase, ectonucleoside triphosphate
diphosphohydrolase 4, ATP-binding cassette, subfamily C, member 1, transforming growth
factor-β, and prostaglandin E receptor 2; increased expression of cytochrome P450, family 4,
subfamily F, polypeptide 3, and glutathione peroxidase 3; and abnormalities in the immune
system, nucleic acid metabolism, arachidonic acid/leukotriene pathways, and biological
processes. These results suggested that IPH involved compromised function of
immunocompetent cells and that such dysfunction may be associated with abnormalities in
nucleic acid metabolism and arachidonic acid/leukotriene-related synthesis/metabolism.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.